Altimmune (NASDAQ:ALT) Stock: Insider Jerome Benedict Durso Purchases 30,700 Shares

Key Points

• Altimmune CEO Jerome Durso bought 30,700 shares at an average $1.62, spending $49,734. The purchase increased his direct stake by 49.12% to 93,200 shares.
• ALT shares traded at $1.66 on Friday, near the reported one-year low of $1.58; the stock’s 50-day and 200-day moving averages were $2.62 and $3.17.
• The company reported a third-quarter loss of $0.15 per share, missing the $0.13 loss analysts expected. Separately, new Phase 2b data for pemvidutide showed improvements in MASH measures and support for the ongoing Phase 3 trial.

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) CEO Jerome Durso acquired 30,700 shares of the company's stock in a transaction on Friday, November 13th. The stock was acquired at an average price of $1.62 per share, with a total value of $49,734.00. Following the purchase, the chief executive officer directly owned 93,200 shares in the company, valued at approximately $150,984. This represents a 49.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Altimmune Price Performance

Shares of ALT stock traded up $0.04 during trading on Friday, hitting $1.66. The company had a trading volume of 3,501,696 shares, compared to its average volume of 4,245,085. The firm has a market capitalization of $321.93 million, a P/E ratio of -2.12 and a beta of 0.16. Altimmune, Inc. has a one year low of $1.58 and a one year high of $6.44. The company has a debt-to-equity ratio of 0.07, a quick ratio of 26.78 and a current ratio of 26.78. The stock's 50-day moving average price is $2.62 and its 200 day moving average price is $3.17.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). Equities analysts expect that Altimmune, Inc. will post -0.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Altimmune

Several hedge funds and other institutional investors have recently modified their holdings of ALT. Dimensional Fund Advisors LP grew its position in Altimmune by 268.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company's stock valued at $3,221,000 after acquiring an additional 762,223 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Altimmune during the second quarter worth about $2,097,000. Bank of America Corp DE lifted its holdings in shares of Altimmune by 48.6% in the first quarter. Bank of America Corp DE now owns 570,203 shares of the company's stock worth $1,756,000 after acquiring an additional 186,420 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Altimmune by 156.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company's stock worth $1,575,000 after acquiring an additional 316,209 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Altimmune by 69.4% in the second quarter. Wellington Management Group LLP now owns 420,300 shares of the company's stock worth $1,278,000 after acquiring an additional 172,142 shares during the last quarter. Institutional investors own 78.05% of the company's stock.

Top Altimmune Stories

These are some of the ALT stories that stood out recently:

• Positive Sentiment: New 48-week Phase 2b IMPACT data showed significant improvements in measures of liver fat, inflammation and fibrosis, alongside weight loss and generally favorable tolerability for investigational pemvidutide in MASH. The results were published in The Lancet Gastroenterology & Hepatology and support the ongoing Phase 3 PERFORMA trial. Article
• Positive Sentiment: B. Riley reaffirmed its “buy” rating, signaling continued analyst support. Article
• Negative Sentiment: Third-quarter loss per share was $0.15, wider than the $0.13 consensus estimate. Higher research and development costs are pressuring results, and investors remain focused on the capital required to advance the pipeline despite the reported cash runway. Article

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Altimmune in a research note on Monday, September 21st. Citigroup reiterated a "market outperform" rating on shares of Altimmune in a research note on Friday. Evercore reissued an "outperform" rating on shares of Altimmune in a report on Wednesday, September 23rd. B. Riley Financial restated a "buy" rating on shares of Altimmune in a research report on Friday. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Altimmune in a report on Tuesday, July 28th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $14.33.

Altimmune Company Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune's work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.